InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,303.27
(
0.12%
)
US TECH 100
18,062.80
(
-0.09%
)
Dow Jones
40,003.59
(
0.34%
)
Brent Oil
83.75
(
0.65%
)
Bitcoin
66,911.20
(
2.56%
)
Post# of 109
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

dcaf7

Send PM Follow Ignore
Followers 3
Posts 287
Boards Moderated 0
Alias Born 12/21/2022

dcaf7

Re: None

Wednesday, 04/24/2024 11:07:47 AM

Wednesday, April 24, 2024 11:07:47 AM

Post# of 109
Title of the second abstract, "Phase 1 study of BDTX-1535, an oral 4th generation covalent EGFR inhibitor, in patients with recurrent glioblastoma: Preliminary dose escalation results".
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent BDTX News
More BDTX News
InvestorsHub NewsWire

FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM

Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM

VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM

ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM

Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM

Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM

Start posting your company's news
Only $200 per official company press release!